Strategies to design AML vaccines include administration of Wilms’ tumor 1 (WT1) peptide with adjuvant [77, 78], DCs with WT1 tumor antigens [79, 80], or DCleu [56]. The gene discussed is WT1; the disease is acute myeloid leukemia.